Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ursodeoxycholic acid + biphenyl dimethyl dicarboxylate
- Development stage
- Phase 3
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-230 is a fixed-dose combination (FDC) therapy developed by Addpharma (a subsidiary of Yuhan Corporation) for the treatment of chronic liver disease. It consists of ursodeoxycholic acid (UDCA), a naturally occurring bile acid that improves bile flow and protects liver cells from toxic bile acids, and biphenyl dimethyl dicarboxylate (BDD), a synthetic derivative of schisandrin C that helps reduce elevated liver enzyme levels (ALT/AST) and provides hepatoprotective effects. The combination is designed to provide synergistic benefits in managing liver function in patients with chronic hepatitis or other chronic liver conditions. AD-230 was approved in South Korea in 2021 under the brand name Uridic.
- Brand names
- Uridic
- Other names
- UDCA/BDD combinationUDCA/DDB combination
02
Targets
FXR (Farnesoid x-activated receptor)GPBAR1
Beyond the preview
Go deeper on ursodeoxycholic acid + biphenyl dimethyl dicarboxylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ursodeoxycholic acid + biphenyl dimethyl dicarboxylate.